Cargando…
Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses
BACKGROUND & AIMS: HBV exhibits wide genetic diversity with at least 9 genotypes (GTs), which differ in terms of prevalence, geographic distribution, natural history, disease progression, and treatment outcome. However, differences in HBV replicative capacity, gene expression, and infective capa...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403497/ https://www.ncbi.nlm.nih.gov/pubmed/36035359 http://dx.doi.org/10.1016/j.jhepr.2022.100535 |
_version_ | 1784773390906687488 |
---|---|
author | Liu, Yongzhen Park, Debby Cafiero, Thomas R. Bram, Yaron Chandar, Vasuretha Tseng, Anna Gertje, Hans P. Crossland, Nicholas A. Su, Lishan Schwartz, Robert E. Ploss, Alexander |
author_facet | Liu, Yongzhen Park, Debby Cafiero, Thomas R. Bram, Yaron Chandar, Vasuretha Tseng, Anna Gertje, Hans P. Crossland, Nicholas A. Su, Lishan Schwartz, Robert E. Ploss, Alexander |
author_sort | Liu, Yongzhen |
collection | PubMed |
description | BACKGROUND & AIMS: HBV exhibits wide genetic diversity with at least 9 genotypes (GTs), which differ in terms of prevalence, geographic distribution, natural history, disease progression, and treatment outcome. However, differences in HBV replicative capacity, gene expression, and infective capability across different GTs remain incompletely understood. Herein, we aimed to study these crucial aspects using newly constructed infectious clones covering the major HBV GTs. METHODS: The replicative capacity of infectious clones covering HBV GTs A-E was analyzed in cell lines, primary hepatocytes and humanized mice. Host responses and histopathology induced by the different HBV GTs were characterized in hydrodynamically injected mice. Differences in treatment responses to entecavir and various HBV capsid inhibitors were also quantified across the different genetically defined GTs. RESULTS: Patient-derived HBV infectious clones replicated robustly both in vitro and in vivo. GTs A and D induce more pronounced intrahepatic and proinflammatory cytokine responses which correlated with faster viral clearance. Notably, all 5 HBV clones robustly produced viral particles following transfection into HepG2 cells, and these particles were infectious in HepG2-NTCP cells, primary human hepatocytes and human chimeric mice. Notably, GT D virus exhibited higher infectivity than GTs A, B, C and E in vitro, although it was comparable to GT A and B in the human liver chimeric mice in vivo. HBV capsid inhibitors were more readily capable of suppressing HBV GTs A, B, D and E than C. CONCLUSIONS: The infectious clones described here have broad utility as genetic tools that can mechanistically dissect intergenotypic differences in antiviral immunity and pathogenesis and aid in HBV drug development and screening. LAY SUMMARY: The hepatitis B virus (HBV) is a major contributor to human morbidity and mortality. HBV can be categorized into a number of genotypes, based on their specific genetic make-up, of which 9 are well known. We isolated and cloned the genomes of 5 of these genotypes and used them to create valuable tools for future research on this clinically important virus. |
format | Online Article Text |
id | pubmed-9403497 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-94034972022-08-26 Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses Liu, Yongzhen Park, Debby Cafiero, Thomas R. Bram, Yaron Chandar, Vasuretha Tseng, Anna Gertje, Hans P. Crossland, Nicholas A. Su, Lishan Schwartz, Robert E. Ploss, Alexander JHEP Rep Research Article BACKGROUND & AIMS: HBV exhibits wide genetic diversity with at least 9 genotypes (GTs), which differ in terms of prevalence, geographic distribution, natural history, disease progression, and treatment outcome. However, differences in HBV replicative capacity, gene expression, and infective capability across different GTs remain incompletely understood. Herein, we aimed to study these crucial aspects using newly constructed infectious clones covering the major HBV GTs. METHODS: The replicative capacity of infectious clones covering HBV GTs A-E was analyzed in cell lines, primary hepatocytes and humanized mice. Host responses and histopathology induced by the different HBV GTs were characterized in hydrodynamically injected mice. Differences in treatment responses to entecavir and various HBV capsid inhibitors were also quantified across the different genetically defined GTs. RESULTS: Patient-derived HBV infectious clones replicated robustly both in vitro and in vivo. GTs A and D induce more pronounced intrahepatic and proinflammatory cytokine responses which correlated with faster viral clearance. Notably, all 5 HBV clones robustly produced viral particles following transfection into HepG2 cells, and these particles were infectious in HepG2-NTCP cells, primary human hepatocytes and human chimeric mice. Notably, GT D virus exhibited higher infectivity than GTs A, B, C and E in vitro, although it was comparable to GT A and B in the human liver chimeric mice in vivo. HBV capsid inhibitors were more readily capable of suppressing HBV GTs A, B, D and E than C. CONCLUSIONS: The infectious clones described here have broad utility as genetic tools that can mechanistically dissect intergenotypic differences in antiviral immunity and pathogenesis and aid in HBV drug development and screening. LAY SUMMARY: The hepatitis B virus (HBV) is a major contributor to human morbidity and mortality. HBV can be categorized into a number of genotypes, based on their specific genetic make-up, of which 9 are well known. We isolated and cloned the genomes of 5 of these genotypes and used them to create valuable tools for future research on this clinically important virus. Elsevier 2022-07-09 /pmc/articles/PMC9403497/ /pubmed/36035359 http://dx.doi.org/10.1016/j.jhepr.2022.100535 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Liu, Yongzhen Park, Debby Cafiero, Thomas R. Bram, Yaron Chandar, Vasuretha Tseng, Anna Gertje, Hans P. Crossland, Nicholas A. Su, Lishan Schwartz, Robert E. Ploss, Alexander Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses |
title | Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses |
title_full | Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses |
title_fullStr | Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses |
title_full_unstemmed | Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses |
title_short | Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses |
title_sort | molecular clones of genetically distinct hepatitis b virus genotypes reveal distinct host and drug treatment responses |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403497/ https://www.ncbi.nlm.nih.gov/pubmed/36035359 http://dx.doi.org/10.1016/j.jhepr.2022.100535 |
work_keys_str_mv | AT liuyongzhen molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses AT parkdebby molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses AT cafierothomasr molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses AT bramyaron molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses AT chandarvasuretha molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses AT tsenganna molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses AT gertjehansp molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses AT crosslandnicholasa molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses AT sulishan molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses AT schwartzroberte molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses AT plossalexander molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses |